Zeeshan Haq
Retina Specialist · Edina, MNNPI 1396278438
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,460 of the $12,493 with a category attached, or 91.7%. Genentech USA, Inc. accounts for 81.6% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $10,997, more than ten times the $16 reported in 2023.
Across 12 payments — averaging $1041.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$10K
- Ocular Therapeutix, Inc.$2K
- Bausch & Lomb Americas Inc.$16
Across 5 payments — averaging $3547.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$18K
What the payments were for
- Consulting fees$11,46092%
- Travel & lodging$6535%
- Food & beverage$3793%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 8 | $10,195 |
| Ocular Therapeutix, Inc. | 3 | $2,282 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$9,945
How this compares
$12,493 in reported general payments places this provider in the 85th percentile of 20 retina specialist providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 242 | $12,732 |
| Ketorolac Tromethamine | 174 | $3,922 |
| Atropine Sulfate | 113 | $3,740 |
| Brimonidine Tartrate | 16 | $1,016 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 105 | $722 |
| ValacyclovirValacyclovir Hcl | 20 | $685 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $379 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Edina
- Michael MaywoodEdina$5K
- Guneet SodhiEdina$3K
- Sahal SalehEdina$3K
- Vincent VannEdina$300
- Richard JohnstonEdina$284
- Tommaso VagagginiEdina$139
- Paul DraynaEdina$28
- Malav JoshiRochester$293K
- Abdhish BhavsarMinneapolis$21K
- David WilliamsBaxter$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.